Search

Now showing items 1-10 of 13

Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population

Nasrallah, Gheyath K; Dargham, Soha R; Shurrab, Farah; Al-Sadeq, Duaa W; Al-Jighefee, Hadeel; ... more authors ... less authors ( Nature Research , 2021 , Article)

Performance of three automated commercial serological IgG-based assays was investigated for assessing SARS-CoV-2 "ever" (past or current) infection in a population-based sample in a high exposure setting. PCR and serological ...

Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February-18 April 2020

Al Kuwari, Hanan M.; Abdul Rahim, Hanan F.; Abu-Raddad, Laith J.; Abou-Samra, Abdul Badi; Al Kanaani, Zaina; ... more authors ... less authors ( BMJ Publishing Group , 2020 , Article)

© Authors 2020 Objective To define the epidemiological curve of COVID-19 in Qatar and determine factors associated with severe or critical illness. Design Case series of first 5685 COVID-19 cases in Qatar. Setting and ...

Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months

Laith J., Abu-Raddad; Chemaitelly, Hiam; Malek, Joel A.; Ahmed, Ayeda A.; Mohamoud, Yasmin A.; ... more authors ... less authors ( Elsevier , 2021 , Article)

We document two cases of viremic and prolonged active infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) where the viral genome was conserved for two months, but infection was with little or ...

Severity, criticality, and fatality of the SARS-CoV-2 Beta variant

Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; Yassine, Hadi M; Benslimane, Fatiha M; ... more authors ... less authors ( Oxford Academic , 2021 , Article)

Beta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to ...

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.

Tang, Patrick; Hasan, Mohammad R; Chemaitelly, Hiam; Yassine, Hadi M; Benslimane, Fatiha M; ... more authors ... less authors ( Nature Researc , 2021 , Article)

With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines ...

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar.

Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; Yassine, Hadi M; Benslimane, Fatiha M; ... more authors ... less authors ( American Medical Association , 2021 , Article)

The effect of prior SARS-CoV-2 infection on vaccine protection remains poorly understood. To assess protection from SARS-CoV-2 breakthrough infection after mRNA vaccination among persons with vs without prior SARS-CoV-2 ...

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.

Abu-Raddad, Laith J; Chemaitelly, Hiam; Yassine, Hadi M; Benslimane, Fatiha M; Al Khatib, Hebah A; ... more authors ... less authors ( Oxford University Press , 2021 , Article)

Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across countries. A key question is whether delaying administration of the second vaccine dose to vaccinate the largest number of ...

SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar.

Al-Thani, Mohamed H; Farag, Elmoubasher; Bertollini, Roberto; Al Romaihi, Hamad Eid; Abdeen, Sami; ... more authors ... less authors ( Oxford University Press , 2021 , Article)

Qatar experienced a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic that disproportionately affected the craft and manual worker (CMW) population, who comprise 60% of the total population. This study ...

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

Laith J., Abu-Raddad; Chemaitelly, Hiam; Coyle, Peter; Malek, Joel A.; Ahmed, Ayeda A.; ... more authors ... less authors ( Elsevier , 2021 , Article)

BackgroundReinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons ...

SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals

Peter V., Coyle; Chemaitelly, Hiam; Ben Hadj Kacem, Mohamed Ali; Abdulla Al Molawi, Naema Hassan; El Kahlout, Reham Awni; ... more authors ... less authors ( Elsevier , 2021 , Article)

The study objective was to the assess level of detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the urban population of Qatar. Antibody testing was performed on residual blood specimens ...